J.Safra Asset Management Corp Takes Position in Quest Diagnostics Incorporated $DGX

J.Safra Asset Management Corp purchased a new position in shares of Quest Diagnostics Incorporated (NYSE:DGX) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 4,621 shares of the medical research company’s stock, valued at approximately $979,000.

Other institutional investors have also recently bought and sold shares of the company. Norges Bank bought a new stake in Quest Diagnostics in the fourth quarter valued at approximately $229,522,000. Boston Partners boosted its stake in shares of Quest Diagnostics by 32.8% during the 3rd quarter. Boston Partners now owns 4,036,881 shares of the medical research company’s stock worth $767,978,000 after acquiring an additional 997,033 shares during the period. EdgePoint Investment Group Inc. increased its holdings in shares of Quest Diagnostics by 95.5% during the 4th quarter. EdgePoint Investment Group Inc. now owns 1,661,072 shares of the medical research company’s stock worth $288,246,000 after acquiring an additional 811,320 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in Quest Diagnostics in the 2nd quarter valued at $133,388,000. Finally, UBS Group AG lifted its holdings in Quest Diagnostics by 67.8% during the 4th quarter. UBS Group AG now owns 1,114,451 shares of the medical research company’s stock valued at $193,391,000 after purchasing an additional 450,161 shares during the last quarter. Institutional investors and hedge funds own 88.06% of the company’s stock.

Quest Diagnostics Stock Up 0.0%

Shares of NYSE:DGX opened at $234.48 on Monday. The company has a fifty day moving average of $215.60 and a 200-day moving average of $203.32. The company has a market capitalization of $25.88 billion, a PE ratio of 24.89, a price-to-earnings-growth ratio of 2.16 and a beta of 0.56. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.46 and a current ratio of 1.59. Quest Diagnostics Incorporated has a 52-week low of $171.18 and a 52-week high of $240.13.

Quest Diagnostics (NYSE:DGX) last released its quarterly earnings data on Thursday, July 23rd. The medical research company reported $3.12 earnings per share for the quarter, beating the consensus estimate of $2.82 by $0.30. The company had revenue of $3.04 billion for the quarter, compared to the consensus estimate of $2.97 billion. Quest Diagnostics had a return on equity of 16.01% and a net margin of 9.18%.Quest Diagnostics’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same quarter last year, the business posted $2.62 EPS. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. On average, equities analysts predict that Quest Diagnostics Incorporated will post 11.15 EPS for the current fiscal year.

Quest Diagnostics Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 21st. Stockholders of record on Tuesday, October 6th will be issued a dividend of $0.86 per share. This represents a $3.44 dividend on an annualized basis and a dividend yield of 1.5%. The ex-dividend date is Tuesday, October 6th. Quest Diagnostics’s payout ratio is 36.52%.

Insider Buying and Selling at Quest Diagnostics

In other news, SVP Mark E. Delaney sold 1,600 shares of the business’s stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $235.18, for a total value of $376,288.00. Following the transaction, the senior vice president owned 10,335 shares in the company, valued at approximately $2,430,585.30. The trade was a 13.41% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO J. E. Davis sold 10,000 shares of the company’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $194.14, for a total transaction of $1,941,400.00. Following the completion of the sale, the chief executive officer directly owned 132,423 shares in the company, valued at approximately $25,708,601.22. This represents a 7.02% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 19,747 shares of company stock worth $3,947,088. Insiders own 0.88% of the company’s stock.

Key Headlines Impacting Quest Diagnostics

Here are the key news stories impacting Quest Diagnostics this week:

• Positive Sentiment: Broad-based earnings estimate increases: Zacks Research raised its FY2026 EPS forecast to $11.15 from $10.66, FY2027 to $11.71 from $11.50, and FY2028 to $12.90 from $12.50. The firm also increased estimates for Q3 and Q4 2026, Q1 through Q3 2027, and Q1 and Q2 2028. These revisions suggest improving expectations for Quest Diagnostics’ earnings growth. MarketBeat analyst estimate updates
• Positive Sentiment: Momentum remains favorable: A Zacks analysis highlighted DGX’s 2.29% weekly gain and evaluated whether the stock can continue to attract momentum investors. The coverage may reinforce positive sentiment following the recent advance. Quest Diagnostics Is Up 2.29% in One Week
• Positive Sentiment: Dividend support: Quest Diagnostics declared a quarterly dividend of $0.86 per share, payable October 21 to shareholders of record October 6. The annualized yield is approximately 1.5%, providing ongoing shareholder income. Quest Diagnostics dividend announcement
• Neutral Sentiment: One estimate was lowered: Zacks reduced its Q4 2027 EPS forecast to $2.90 from $3.05, partially offsetting the otherwise positive revisions. The firm’s full-year 2027 and 2028 forecasts nevertheless remain higher than its previous estimates.

Analyst Upgrades and Downgrades

Several equities analysts have commented on DGX shares. JPMorgan Chase & Co. upped their price objective on shares of Quest Diagnostics from $220.00 to $250.00 and gave the company a “neutral” rating in a report on Tuesday, July 28th. Argus set a $260.00 price objective on Quest Diagnostics in a report on Wednesday, July 29th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $245.00 target price on shares of Quest Diagnostics in a research report on Thursday, July 23rd. UBS Group increased their target price on Quest Diagnostics from $220.00 to $232.00 and gave the stock a “neutral” rating in a research note on Friday, July 24th. Finally, Barclays lifted their target price on Quest Diagnostics from $230.00 to $250.00 and gave the stock an “overweight” rating in a report on Thursday, July 23rd. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and seven have issued a Hold rating to the company. Based on data from MarketBeat.com, Quest Diagnostics has an average rating of “Moderate Buy” and an average target price of $235.31.

Quest Diagnostics Company Profile

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.